ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Abbott Offers New Education Awards

June 12, 1987

In Brief: General Motors Cancer Prizes Awarded; Thomas Promoted; HIV Research funding

June 24, 1994

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

Supreme Court Lets Stand Lower Court Ruling On AZT Patents

January 19, 1996

NIH Policy On Diversity In Sponsored Meetings

June 16, 1995

In Brief: Tomasi To Resign As Roswell Park President; Committee To Study NIH Grant Review Issues

December 15, 1995